Literature DB >> 9676778

Anti-centromere autoantibody in a patient evolving from a lupus/Sjögren's overlap to the CREST variant of scleroderma.

A L Ford1, B T Kurien, J B Harley, R H Scofield.   

Abstract

We characterized the development of the anti-centromere antibody in a patient prior to the development of CREST (calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, telangiectasias) symptoms. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis followed by immunoblotting (IgG and IgM) of cellular extracts enriched for centromere antigens and indirect immunofluorescence were used to study the anti-centromere immune response. The sera recognized 3 centromere antigens with molecular masses 18,000 (CENP-A), 50,000 (CENP-D), and 80,000 (CENP-B). For CENP-A, IgM was present before the appearance of the IgG response. Anti-CENP-D revealed an IgM response that decreased over time but no IgG, while CENP-B showed an IgG response that strengthened and then weakened over time. The appearance of an anti-centromere nuclear fluorescence pattern correlated with the appearance of IgG anti-CENP-A. Signs and symptoms typical of CREST began about 4 years after antibodies to centromere antigens were found. The development of the CREST syndrome in our patient was preceded by the appearance of anti-centromere autoantibodies. For at least one of the antigens (CENP-A), there was an immunoglobulin class switch from IgM to IgG.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9676778

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  6 in total

1.  Distinct recognition of antibodies to centromere proteins in primary Sjogren's syndrome compared with limited scleroderma.

Authors:  A C Gelber; S R Pillemer; B J Baum; F M Wigley; L K Hummers; S Morris; A Rosen; L Casciola-Rosen
Journal:  Ann Rheum Dis       Date:  2006-01-13       Impact factor: 19.103

2.  Clinical significance and diagnostic usefulness of anti-centromere antibody in Sjögren's syndrome.

Authors:  Tetsutaro Kitagawa; Koichi Shibasaki; Shuji Toya
Journal:  Clin Rheumatol       Date:  2011-06-14       Impact factor: 2.980

3.  New centromere autoantigens identified in systemic sclerosis using centromere protein microarrays.

Authors:  Guang Song; Chaojun Hu; Heng Zhu; Li Wang; Fengchun Zhang; Yongzhe Li; Lin Wu
Journal:  J Rheumatol       Date:  2013-02-15       Impact factor: 4.666

4.  Clinical and serological evaluation of a novel CENP-A peptide based ELISA.

Authors:  Michael Mahler; Liesbeth Maes; Daniel Blockmans; Rene Westhovens; Xavier Bossuyt; Gabriela Riemekasten; Sandra Schneider; Falk Hiepe; Andreas Swart; Irmgard Gürtler; Karl Egerer; Margrit Fooke; Marvin J Fritzler
Journal:  Arthritis Res Ther       Date:  2010-05-20       Impact factor: 5.156

Review 5.  The clinical relevance of autoantibodies in scleroderma.

Authors:  Khanh T Ho; John D Reveille
Journal:  Arthritis Res Ther       Date:  2003-02-12       Impact factor: 5.156

6.  Correlation between centromere protein-F autoantibodies and cancer analyzed by enzyme-linked immunosorbent assay.

Authors:  Simon Welner; Nicole Hartwig Trier; Morten Frisch; Henning Locht; Paul Robert Hansen; Gunnar Houen
Journal:  Mol Cancer       Date:  2013-08-26       Impact factor: 27.401

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.